{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:01:56Z","timestamp":1779847316364,"version":"3.53.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SD Ireland Cancer Research Fund"},{"DOI":"10.13039\/100003482","name":"John Wayne Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46751-z","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:23:16Z","timestamp":1775456596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Stephanie C.","family":"Pero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girja S.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Barrantes-Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"3","key":"46751_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng.3489","volume":"48","author":"MJ Williams","year":"2016","unstructured":"Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48(3), 238\u201344 (2016).","journal-title":"Nat. Genet."},{"issue":"2","key":"46751_CR2","first-page":"728","volume":"43","author":"PH Hand","year":"1983","unstructured":"Hand, P. H., Nuti, M., Colcher, D. & Schlom, J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res. 43(2), 728\u201335 (1983).","journal-title":"Cancer Res."},{"issue":"4","key":"46751_CR3","doi-asserted-by":"publisher","DOI":"10.1098\/rsfs.2013.0020","volume":"3","author":"D Basanta","year":"2013","unstructured":"Basanta, D. & Anderson, A. R. Exploiting ecological principles to better understand cancer progression and treatment. Interface Focus 3(4), 20130020 (2013).","journal-title":"Interface Focus"},{"issue":"1","key":"46751_CR4","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk, A. & Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 1805(1), 105\u2013117 (2010).","journal-title":"Biochim. Biophys. Acta"},{"issue":"7381","key":"46751_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481 (7381), 306\u2013313 (2012).","journal-title":"Nature"},{"issue":"4","key":"46751_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4143\/crt.2021.835","volume":"54","author":"TXM Tran","year":"2022","unstructured":"Tran, T. X. M. et al. Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors. Cancer Res. Treat. 54 (4), 1065\u20131073 (2022).","journal-title":"Cancer Res. Treat."},{"issue":"7","key":"46751_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N. Engl. J. Med. 382(7), 597\u2013609 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"46751_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 6 (1), 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"issue":"10371","key":"46751_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371), 105\u201317 (2023).","journal-title":"Lancet"},{"issue":"9","key":"46751_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382(9), 810\u201321 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"46751_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ymeth.2013.06.020","volume":"65","author":"R Braster","year":"2014","unstructured":"Braster, R., O\u2019Toole, T. & van Egmond, M. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 65 (1), 28\u201337 (2014).","journal-title":"Methods"},{"issue":"6","key":"46751_CR12","first-page":"839","volume":"33","author":"JE Parrillo","year":"1977","unstructured":"Parrillo, J. E. & Fauci, A. S. Apparent direct cellular cytotoxicity mediated via cytophilic antibody. Multiple Fc receptor bearing effector cell populations mediating cytophilic antibody induced cytotoxicity. Immunology 33(6), 839\u201350 (1977).","journal-title":"Immunology"},{"key":"46751_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.06.005","volume":"59","author":"S Parakh","year":"2017","unstructured":"Parakh, S. et al. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat. Rev. 59, 1\u201321 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"46751_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5402-1","volume":"19","author":"P Narang","year":"2019","unstructured":"Narang, P., Chen, M., Sharma, A. A., Anderson, K. S. & Wilson, M. A. The neoepitope landscape of breast cancer: Implications for immunotherapy. BMC Cancer 19, 1\u201310 (2019).","journal-title":"BMC Cancer"},{"issue":"4","key":"46751_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2217\/imt-2016-0146","volume":"9","author":"CA Brennick","year":"2017","unstructured":"Brennick, C. A., George, M. M., Corwin, W. L., Srivastava, P. K. & Ebrahimi-Nik, H. Neoepitopes as cancer immunotherapy targets: Key challenges and opportunities. Immunotherapy 9(4), 361\u201371 (2017).","journal-title":"Immunotherapy"},{"issue":"7","key":"46751_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/bit.28387","volume":"120","author":"S Joubert","year":"2023","unstructured":"Joubert, S. et al. A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens. Biotechnol. Bioeng. 120(7), 1746\u201361 (2023).","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"46751_CR17","first-page":"349","volume":"52","author":"SC Pero","year":"2022","unstructured":"Pero, S. C. et al. Development of clinical-grade antibodies against tumor-specific mutations to target neuroblastoma. Ann. Clin. Lab. Sci. 52(3), 349\u201358 (2022).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"46751_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s12094-019-02235-3","volume":"22","author":"G Shukla","year":"2020","unstructured":"Shukla, G. et al. Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models. Clin. Transl. Oncol. 22, 1094\u2013104 (2020).","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"46751_CR19","first-page":"735","volume":"49","author":"SC Rockwell","year":"1972","unstructured":"Rockwell, S. C., Kallman, R. F. & Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49(3), 735\u201349 (1972).","journal-title":"J. Natl. Cancer Inst."},{"key":"46751_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trsl.2024.05.001","volume":"271","author":"Y Xiao","year":"2024","unstructured":"Xiao, Y. et al. Progesterone receptor impairs immune respond and down-regulates sensitivity to anti-LAG3 in breast cancer. Transl Res. 271, 68\u201378 (2024).","journal-title":"Transl Res."},{"key":"46751_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2022.113362","volume":"510","author":"GS Shukla","year":"2022","unstructured":"Shukla, G. S., Pero, S. C., Mei, L., Sun, Y.-J. & Krag, D. N. Targeting of palpable B16-F10 melanoma tumors with polyclonal antibodies on white blood cells. J. Immunol. Methods 510, 113362 (2022).","journal-title":"J. Immunol. Methods"},{"key":"46751_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112720","volume":"478","author":"GS Shukla","year":"2020","unstructured":"Shukla, G. S., Sun, Y.-J., Pero, S. C. & Krag, D. N. A cocktail of polyclonal affinity enriched antibodies against melanoma mutations increases binding and inhibits tumor growth. J. Immunol. Methods 478, 112720 (2020).","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"46751_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8(1), 95 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"46751_CR24","doi-asserted-by":"crossref","unstructured":"Benvenuto, M. et al. (eds) Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Seminars in Cancer Biology; : Elsevier. (2021).","DOI":"10.1016\/j.semcancer.2019.10.023"},{"key":"46751_CR25","doi-asserted-by":"crossref","unstructured":"Sun, Y. et al. Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques ;52(4). (2012).","DOI":"10.2144\/000113855"},{"issue":"463","key":"46751_CR26","doi-asserted-by":"publisher","first-page":"eaat5775","DOI":"10.1126\/scitranslmed.aat5775","volume":"10","author":"D Slaga","year":"2018","unstructured":"Slaga, D. et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2\/CD3. Sci. Transl. Med. 10 (463), eaat5775 (2018).","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"46751_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","volume":"21","author":"SC Oostindie","year":"2022","unstructured":"Oostindie, S. C., Lazar, G. A., Schuurman, J. & Parren, P. W. Avidity in antibody effector functions and biotherapeutic drug design. Nat. Rev. Drug Discov. 21(10), 715\u201335 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"46751_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.trecan.2023.02.004","volume":"9","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Neoantigen-directed therapeutics in the clinic: Where are we?. Trends Cancer 9(6), 503\u201319 (2023).","journal-title":"Trends Cancer"},{"issue":"5","key":"46751_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/eji.202149766","volume":"52","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur. J. Immunol. 52(5), 753\u20139 (2022).","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"46751_CR30","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","volume":"189","author":"MB Overdijk","year":"2012","unstructured":"Overdijk, M. B. et al. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189(7), 3430\u20138 (2012).","journal-title":"J. Immunol."},{"issue":"5","key":"46751_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs 9 (5), 767\u2013773 (2017).","journal-title":"MAbs"},{"issue":"4","key":"46751_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2021.03.009","volume":"54","author":"BM Gunn","year":"2021","unstructured":"Gunn, B. M. et al. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 54(4), 815\u201328.e5 (2021).","journal-title":"Immunity"},{"issue":"6","key":"46751_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.immuni.2025.05.004","volume":"58","author":"PS Grace","year":"2025","unstructured":"Grace, P. S. et al. Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction. Immunity 58(6), 1586\u201397.e5 (2025).","journal-title":"Immunity"},{"issue":"2","key":"46751_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101417","volume":"5","author":"MD Slein","year":"2024","unstructured":"Slein, M. D. et al. Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D. Cell Rep. Med. 5(2), 101417 (2024).","journal-title":"Cell Rep. Med."},{"key":"46751_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143129","author":"C Atyeo","year":"2021","unstructured":"Atyeo, C. et al. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.143129 (2021).","journal-title":"JCI Insight"},{"issue":"795","key":"46751_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk6745","volume":"17","author":"NK Kisalu","year":"2025","unstructured":"Kisalu, N. K. et al. Fc\u03b3r binding differentially contributes to protection by two human monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein. Sci. Transl. Med. 17(795), eadk6745 (2025).","journal-title":"Sci. Transl. Med."},{"key":"46751_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.molimm.2017.12.006","volume":"94","author":"G Dekkers","year":"2018","unstructured":"Dekkers, G. et al. Conserved Fc\u03b3r- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. Mol. Immunol. 94, 54\u201360 (2018).","journal-title":"Mol. Immunol."},{"issue":"2","key":"46751_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers13020312","volume":"13","author":"KJ Dixon","year":"2021","unstructured":"Dixon, K. J., Wu, J. & Walcheck, B. Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells. Cancers 13 (2), 312 (2021).","journal-title":"Cancers"},{"issue":"1","key":"46751_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions. Mol. Cancer 21(1), 28 (2022).","journal-title":"Mol. Cancer"},{"issue":"5","key":"46751_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","volume":"180","author":"HY Chew","year":"2020","unstructured":"Chew, H. Y. et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell 180(5), 895-914. e27 (2020).","journal-title":"Cell"},{"issue":"8","key":"46751_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12080836","volume":"12","author":"L Rocha","year":"2024","unstructured":"Rocha, L., Guimar\u00e3es, P. A. S., Carvalho, M. G. R. & Ruiz, J. C. Tumor neoepitope-based vaccines: A scoping review on current predictive computational strategies. Vaccines 12(8), 836 (2024).","journal-title":"Vaccines"},{"issue":"1","key":"46751_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns, P. & J\u00f6nsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268 (1), 25\u201351 (2015).","journal-title":"Immunol. Rev."},{"issue":"115","key":"46751_CR43","doi-asserted-by":"publisher","first-page":"eady7328","DOI":"10.1126\/sciimmunol.ady7328","volume":"11","author":"KFA Van Damme","year":"2026","unstructured":"Van Damme, K. F. A. et al. Cross-species cellular mapping and humanization of Fc\u03b3 receptors to advance antibody modeling. Sci. Immunol. 11 (115), eady7328 (2026).","journal-title":"Sci. Immunol."},{"issue":"24","key":"46751_CR44","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","volume":"119","author":"P Bruhns","year":"2012","unstructured":"Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (24), 5640\u20135649 (2012).","journal-title":"Blood"},{"key":"46751_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2019.103613","volume":"213","author":"M Soudy","year":"2020","unstructured":"Soudy, M. et al. UniprotR: Retrieving and visualizing protein sequence and functional information from Universal Protein Resource (UniProt knowledgebase). J. Proteomics 213, 103613 (2020).","journal-title":"J. Proteomics"},{"issue":"D1","key":"46751_CR46","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"UniProt","year":"2023","unstructured":"UniProt. The Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51(D1), D523-d31 (2023).","journal-title":"Nucleic Acids Res."},{"key":"46751_CR47","unstructured":"Team RC. R: A language and environment for statistical computing (Foundation for Statistical Computing, 2013)."},{"issue":"394","key":"46751_CR48","first-page":"165","volume":"770","author":"J Allaire","year":"2012","unstructured":"Allaire, J. & Boston RStudio: integrated development environment for R. MA ;770(394):165\u2013171. (2012).","journal-title":"MA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46751-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46751-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46751-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:04:06Z","timestamp":1779843846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46751-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46751"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46751-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study following the University Vermont Institutional Review Board Regulations (Study #00000317). All animal work was completed in accordance with University of Vermont Institutional Animal Care and Use Committee (Protocol #18\u2009\u2212\u2009002). All animal work was performed in accordance with the ARRIVE guidelines. This study was performed in accordance with the ethical standards as defined in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"16397"}}